Nov 5, 2020 · VelosBio Inc. is a clinical-stage biopharmaceutical company committed to transforming the lives of patients with cancer by developing first-in-class therapies targeting ROR1. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic malignancies and solid tumors.

Trademark applications and grants for Velosbio Inc.. Velosbio Inc. has 3 trademark applications. The latest application filed is for "a symbol or image mark"

VelosBio is a next-generation oncology company, developing novel antibody-drug conjugates to treat haematological cancers. View contacts for VelosBio to access new leads and connect with decision-makers.

Nov 5, 2020 · Merck has struck a deal to buy VelosBio for $2.75 billion. The takeover will give Merck control of an antibody-drug conjugate (ADC) that caused objective responses in 80% of previously treated...

Nov 19, 2020 · Pharma giant Merck has entered into a definitive agreement to acquire oncology biotech VelosBio for $2.75bn in cash. The acquisition remains subject to certain customary adjustments and conditions; the deal is expected to be closed by the end of 2020.

Nov 5, 2020 · Merck & Co Inc said on Thursday it agreed to acquire privately held VelosBio for $2.75 billion in cash, in a move that will help it strengthen its cancer drug portfolio.

VelosBio is a near-term, clinical-stage, biopharmaceutical company focused on a first-in-class antibody drug candidate (ADC) platform. The company was spun-out from Oncternal Therapeutics in 2017 and holds exclusive access and rights to …

Nov 5, 2020 · Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors. This morning, Merck announced it will acquire San Diego-based VelosBio in an all-cash deal.

Mar 10, 2025 · Velosbio doesn't have any recent trademark applications, indicating Velosbio is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and VelosBio Inc. announced that the companies have entered into a definitive agreement pursuant to which MSD, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments.